Cellectar regains Nasdaq compliance via $35M+ market value of listed securities

Cellectar Biosciences, Inc.

Nasdaq notified Cellectar on Nov 21, 2023, that it meets the $35M minimum market value of listed securities under Rule 5550(b)(2), resolving the deficiency.
Prior deficiency: stockholders' equity was $(467,000) as of June 30, 2023, below the $2.5M minimum required under Rule 5550(b)(1).
The company had been at risk of delisting since August 16, 2023; compliance is now fully restored.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.